目的 研究大鼠服用丹酚酸B合用匹伐他汀后药动学及肝细胞摄取能力的改变。方法 将SD雄性大鼠随机分为两组,每组6只,实验一组单用丹酚酸B (2.5 g/kg)给药;另一组丹酚酸B合用匹伐他汀(0.5 mg/kg)。两药合用时先丹酚酸B后匹伐他汀相继灌胃,间隔15 min,眼球静脉取血,探讨有机阴离子转运多肽 (organic anion transporting polypeptides, OATP)底物匹伐他汀对丹酚酸B的药动学影响。然后,游离大鼠原代肝细胞,考察匹伐他汀对大鼠原代肝细胞摄取丹酚酸B的影响。结果 丹酚酸合用匹伐他汀后,丹酚酸B的药动学特性发生明显变化,AUC(0-t)、AUC(0-∞)和Cmax分别增加了54.63%、69.72%、50.56%。随着匹伐他汀浓度增加,其对大鼠原代肝细胞摄取丹酚酸B的抑制作用逐渐增强,IC50为(5.21±1.68)μmol/L。结论 丹酚酸B肝脏转运机制可能与OATP密切相关。
Abstract
Objective To study the pharmacokinetics of salvianolic acid B combined with pitavastatin and the uptaking of salvianolic acid B in rat hepatocytes. Methods SD male rats were randomly divided into two groups (n=6).One group was given salvianolic acid B 2.5 g/kg and another group was given salvianolic acid B combined with pitavastatin 0.5 mg/kg. For combined administration, the salvianolic acid B was first gavaged and then pitavastatin. Interval time lasted about 15 min. Blood samples were collected from the orbital vein. The effect of OATP1B1 substrate of pitavastatin on the pharmacokinetics of salvianolic acid B in rats was examined. Then the primary rat hepatocytes were separated, the effect of pitavastatin on the hepatocytes uptaking of salvianolic acid B was studied. Results The pharmacokinetic characteristics of salvianolic acid B significantly changed when salvianolic acid B was combined with pitavastatin, the parameters of AUC (0-t), AUC (0- ∞) and Cmax were significantly increased by 54.63%, 69.72%, and 50.56%. Simulatneously, the inhibitory action for uptaking of salvianolic acid B in rat hepatocytes increased gradually with increasing pitavastatin concentration. The IC50 was (5.21±1.68) μmol. Conclusions The uptaking of salvianolic acid B in hepatocytes may be closely related to OATP.
关键词
丹酚酸B /
肝脏 /
转运 /
匹伐他汀
Key words
salvianolic acid B /
hepatocytes /
transport /
pitavastatin
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 王 蓉,原永芳. 丹酚酸B 药理作用的研究概况[J]. 中医药导报, 2011, 17(4): 130-132.
[2] 陈 磊,陆 茵,郑仕中. 丹参药理活性成分的整合效应 [J]. 中草药, 2009, 40(3): 476-479.
[3] 侯 俊,张立国,倪力军,等. 双氢丹酚酸B及丹酚酸B在小鼠体内的药动学及组织分布的比较研究[J]. 中药新药与临床药理, 2010, 21(4): 396-399.
[4] ZHAO Di, GAO Zidong, HAN De’en, et al. Influence of rifampicin on the pharmacokinetics of salvianolic acid B may involve inhibition of organic anion transporting polypeptide (Oatp) mediated influx [J] . Phytother Res, 2012, 26: 118-121.
[5] 温金华, 胡锦芳, 蔡 军, 等. 丹参对瑞舒伐他汀在大鼠体内药代动力学的影响[J]. 第二军医大学学报, 2012, 33(3): 320-323.
[6] 张文静, 曹琦琛, 曹 珂, 等. 丹酚酸B的药动学研究进展[J]. 中国新药杂志, 2011, 20(7): 608-612.
[7] 万仁忠, 许妍妍, 谷 元, 等. 丹酚酸B及其活性代谢产物在大鼠体内药动学研究[J]. 中草药, 2011, 42(2): 335-339.
[8] Wen J H, Wu W, Yang D, et al. The role of OATPs /Oatps in pharmacokinetics and drug-drug interaction of cardiovascular agents [J]. Drug Future, 2013, 38(4):257-262.
[9] Takahashi T, Ohtsuka T, Yoshikawa T, et al. Pitavastatin as an in vivo probe for studying hepatic organic anion transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys[J]. Drug Metab Dispos, 2013, 41(10): 1875-1882.
[10] Schuetz J D, Swaan P W, Tweedie D J. The role of transporters in toxicity and disease[J]. Drug Metab Dispos, 2014, 42(4): 541-545.